Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

mTOR Signaling in Growth Control and Disease

Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · see citing works

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Non-viral vectors for gene-based therapy

Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · see citing works

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis

Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · see citing works

Mitochondria as the central control point of apoptosis

Desagher, S., & Martinou, J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01803-1 · Cited by 1,915 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

Bioresponsive materials

Lü, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.75 · Cited by 1,432 · see citing works

Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery

Cheng, R., Feng, F., Meng, F., Deng, C., Feijén, J., & Zhong, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.030 · Cited by 1,367 · see citing works

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

Sui, X., Chen, R. B., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.350 · Cited by 1,209 · see citing works

Reduction-sensitive polymers and bioconjugates for biomedical applications

Meng, F., Hennink, W. E., & Zhong, Z. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.026 · Cited by 1,132 · see citing works

Regulation of autophagy by cytoplasmic p53

Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1730 · Cited by 1,132 · see citing works

Cytoplasmic functions of the tumour suppressor p53

Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912 · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Tools for translation: non-viral materials for therapeutic mRNA delivery

Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799 · see citing works

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S. N., Alsinet, C., Tovar, V., Roayaie, S., Mínguez, B., Solé, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 734 · see citing works

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · see citing works

Microfluidic technologies for accelerating the clinical translation of nanoparticles

Valencia, P. M., Farokhzad, O. C., Karnik, R., & Langer, R. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.168 · Cited by 704 · see citing works

BCL-2 family antagonists for cancer therapy

Lessène, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 623 · see citing works

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

Zhu, A. X., Kudo, M., Assénat, E., Cattan, S., Kang, Y., Lim, H. Y., Poon, R. T. P., Blanc, J., Vogel, A., Chen, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568 · see citing works

Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA

Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540 · see citing works

Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy

Kimura, T., Takabatake, Y., Takahashi, A., & Isaka, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2464 · Cited by 494 · see citing works

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y., Chung, H. C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K., Chìn, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3552 · Cited by 484 · see citing works

Molecular basis of USP7 inhibition by selective small-molecule inhibitors.

Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463 · see citing works

AMP-activated Protein Kinase and the Regulation of Autophagic Proteolysis

Meley, D., Bauvy, C., Houben-Weerts, J. H. P. M., Dubbelhuis, P. F., Helmond, M. T. J., Codogno, P., & Meijer, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605488200 · Cited by 461 · see citing works

Mechanisms of transcriptional regulation by p53

Sullivan, K. D., Galbraith, M. D., Andrysík, Z., & Espinosa, J. M. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.174 · Cited by 455 · see citing works

mTOR signaling and drug development in cancer

Dancey, J. E. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 418 · see citing works

Two‐Dimensional Antimonene‐Based Photonic Nanomedicine for Cancer Theranostics

Tao, W., Ji, X., Zhu, X., Li, L., Wang, J., Zhang, Y., Saw, P. E., Li, W., Kong, N., Islam, M. A., et al. (2018) · Advanced Materials · doi:10.1002/adma.201802061 · Cited by 388 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

Modulation of intracellular ROS levels by TIGAR controls autophagy

Bensaad, K., Cheung, E. C., & Vousden, K. H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.242 · Cited by 361 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle

Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Köhler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G. R., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 349 · see citing works

A dual role of p53 in the control of autophagy

Tasdemir, E., Maiuri, M. C., Morselli, E., Criollo, A., D’Amelio, M., Djavaheri‐Mergny, M., Cecconi, F., Tavernarakis, N., & Kroemer, G. (2008) · Autophagy · doi:10.4161/auto.6486 · Cited by 345 · see citing works

Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA

Islam, M. A., Xu, Y., Tao, W., Ubellacker, J. M., Lim, M., Aum, D., Lee, G. Y., Zhou, K., Zope, H., Yu, M., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0284-0 · Cited by 339 · see citing works

Mitochondrial Proliferation and Paradoxical Membrane Depolarization during Terminal Differentiation and Apoptosis in a Human Colon Carcinoma Cell Line

Mancini, M., Anderson, B. O., Caldwell, E., Sedghinasab, M., Paty, P. B., & Hockenbery, D. M. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.2.449 · Cited by 306 · see citing works

Systemic delivery of factor IX messenger RNA for protein replacement therapy

Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301 · see citing works

Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer

Lim, J., Swami, A., Gilson, L., Chopra, S., Choi, S., Wu, J., Langer, R., Karnik, R., & Farokhzad, O. C. (2014) · ACS Nano · doi:10.1021/nn501371n · Cited by 298 · see citing works

A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295 · see citing works

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263 · see citing works

An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo

Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261 · see citing works

China approves first gene therapy

Pearson, S., Jia, H., & Kandachi, K. (2004) · Nature Biotechnology · doi:10.1038/nbt0104-3 · Cited by 256 · see citing works

Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs

Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247 · see citing works

Mass Production and Size Control of Lipid–Polymer Hybrid Nanoparticles through Controlled Microvortices

Kim, Y., Chung, B. L., Ma, M., et al. (2012) · Nano Letters · doi:10.1021/nl301253v · Cited by 234 · see citing works

Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.

Yokoyama, Y., Dhanabal, M., Griffioen, A. W., Sukhatme, V. P., & Ramakrishnan, S. (2000) · PubMed · Cited by 228 · see citing works

Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance

Ling, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209 · see citing works

Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly

Wagner, K., Claudio, E., Rucker, E. B., Riedlinger, G., Broussard, C., Schwartzberg, P. L., Siebenlist, U. K., & Hennighausen, L. G. (2000) · Development · doi:10.1242/dev.127.22.4949 · Cited by 205 · see citing works

Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment

Zhu, X., Xu, Y., Solis, L. M., Wei, T., Wang, L., Behrens, C., Xu, X., Zhao, L., Liu, D. X., Wu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505629112 · Cited by 200 · see citing works

Hydrophobic Cysteine Poly(disulfide)‐based Redox‐Hypersensitive Nanoparticle Platform for Cancer Theranostics

Wu, J., Zhao, L., Xu, X., Bertrand, N., Choi, W. I., Yameen, B., Shi, J., Shah, V., Mulvale, M., MacLean, J. L., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201503863 · Cited by 193 · see citing works

RNA-based vaccines

Ulmer, J. B., Mason, P. W., Geall, A. J., & Mandl, C. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.060 · Cited by 183 · see citing works

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., Barr, S. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005114107 · Cited by 179 · see citing works

Redox-responsive nanocapsules for intracellular protein delivery

Zhao, M., Biswas, A., Hu, B., Joo, K., Wang, P., Gu, Z., & Tang, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.060 · Cited by 178 · see citing works

Biomaterials for mRNA delivery

Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176 · see citing works

Mechanisms of mTOR inhibitor resistance in cancer therapy

Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161 · see citing works

Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer

Yoshizawa, A., Fukuoka, J., Shimizu, S., Shilo, K., Franks, T. J., Hewitt, S. M., Fujii, T., Cordon‐Cardo, C., Jen, J., & Travis, W. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0986 · Cited by 147 · see citing works

Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency

Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145 · see citing works

Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential

Chauhan, S., Ahmed, Z., Bradfute, S. B., Arko‐Mensah, J., Mandell, M. A., Choi, S. W., Kimura, T., Blanchet, F. P., Waller, A., Mudd, M. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms9620 · Cited by 138 · see citing works

p53 signaling and autophagy in cancer: A revolutionary strategy could be developed for cancer treatment

Sui, X., Jin, L., Huang, X., Geng, S., He, C., & Hu, X. (2011) · Autophagy · doi:10.4161/auto.7.6.14073 · Cited by 137 · see citing works

Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo

Zhu, X., Tao, W., Liu, D. X., Wu, J., Guo, Z., Ji, X., Bharwani, Z., Zhao, L., Zhao, X., Farokhzad, O. C., et al. (2017) · Theranostics · doi:10.7150/thno.18136 · Cited by 134 · see citing works

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Tarhini, A. A., Kotsakis, A. P., Gooding, W. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0802 · Cited by 133 · see citing works

Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.

van Beusechem, V. W., van den Doel, P. B., Grill, J., Pinedo, H. M., & Gerritsen, W. R. (2002) · PubMed · Cited by 132 · see citing works

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

O’Reilly, T., & McSheehy, P. M. J. (2010) · Translational Oncology · doi:10.1593/tlo.09277 · Cited by 127 · see citing works

Biomedical applications of mRNA nanomedicine

Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125 · see citing works

Small molecules that reactivate mutant p53

Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00454-4 · Cited by 123 · see citing works

Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study

Pirollo, K. F., Nemunaitis, J. J., Leung, P. K., Nunan, R., Adams, J., & Chang, E. H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.135 · Cited by 119 · see citing works

Redox‐Responsive Nanoparticle‐Mediated Systemic RNAi for Effective Cancer Therapy

Xu, X., Wu, J., Liu, S., Saw, P. E., Tao, W., Li, Y., Krygsman, L., Yegnasubramanian, S., Marzo, A. M. D., Shi, J., et al. (2018) · Small · doi:10.1002/smll.201802565 · Cited by 115 · see citing works

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise

Mandinova, A., & Lee, S. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001366 · Cited by 113 · see citing works

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53

Zhang, S., Zhou, L., Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Warfel, N. A., Kline, C. L. B., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1079 · Cited by 106 · see citing works

mRNA-based gene transfer as a tool for gene and cell therapy.

Tendeloo, V. F. V., Ponsaerts, P., & Berneman, Z. N. (2007) · PubMed · Cited by 98 · see citing works

AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001

Marinov, M., Ziogas, A., Pardo, O. E., Tan, L. T., Dhillon, T., Mauri, F. A., Lane, H. A., Lemoine, N. R., Zangemeister‐Wittke, U., Seckl, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2166 · Cited by 89 · see citing works

TIGAR Has a Dual Role in Cancer Cell Survival through Regulating Apoptosis and Autophagy

Xie, J., Li, B., Yu, H.-P., Gao, Q.-G., Li, W., Wu, H., & Qin, Z. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3517 · Cited by 84 · see citing works

Inflammation, DAMPs, Tumor Development, and Progression: A Vicious Circle Orchestrated by Redox Signaling

Castellani, P., Balza, E., & Rubartelli, A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5164 · Cited by 77 · see citing works

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives

Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 76 · see citing works

Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma

Rosich, L., Xargay‐Torrent, S., López‐Guerra, M., Campo, E., Colomer, D., & Roué, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0351 · Cited by 70 · see citing works

Translation of angiotensin-converting enzyme 2 upon liver-and lung-targeted delivery of optimized chemically modified mRNA

Schrom, E., Huber, M., Aneja, M., Dohmen, C., Emrich, D., Geiger, J., Hasenpusch, G., Herrmann-Janson, A., Kretzschmann, V., Mykhailyk, O., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.006 · Cited by 69 · see citing works

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0355-8 · Cited by 62 · see citing works

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

Besse, B., Leighl, N. B., Bennouna, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt536 · Cited by 61 · see citing works

Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity

Ventura, A., Vassall, A. N., Robinson, E., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0171 · Cited by 59 · see citing works

NPRL2 enhances autophagy and the resistance to Everolimus in castration‐resistant prostate cancer

Chen, Z., Jiang, Q.-H., Zhu, P.-Y., Chen, Y.-L., Xie, X., Du, Z.-B., Jiang, L., & Tang, W. (2018) · The Prostate · doi:10.1002/pros.23709 · Cited by 47 · see citing works

Stalled Replication Induces p53 Accumulation through Distinct Mechanisms from DNA Damage Checkpoint Pathways

Ho, C. C., Siu, W. Y., Lau, A. W. S., Chan, W. M., Arooz, T., & Poon, R. Y. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1790 · Cited by 36 · see citing works

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells

Harajly, M., Zalzali, H., Nawaz, Z., Ghayad, S. E., Ghamloush, F., Basma, H., Zainedin, S., Rabeh, W., Jabbour, M. N., Tawil, A. N., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00747-15 · Cited by 22 · see citing works

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs

Bykov, V. J. N., Issaeva, N., Zache, N., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.aac117.000815 · Cited by 15 · see citing works

Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

Sallman, D. A., Dezern, A. E., Sweet, K. L., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct068 · Cited by 14 · see citing works

Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery

Azimi, S. M., Sheridan, S. D., Ghannad‐Rezaie, M., Eimon, P. M., & Yanik, M. F. (2018) · eLife · doi:10.7554/elife.31922 · Cited by 11 · see citing works

Ark floats gene therapy's boat, for now

Osborne, R. (2008) · Nature Biotechnology · doi:10.1038/nbt1008-1057 · Cited by 10 · see citing works

Challenges in the gene therapy commercial ecosystem

Kapoor, R., Klueter, T. M., & Wilson, J. M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3931 · Cited by 9 · see citing works

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works

Nanodelivery of nucleic acids

Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · see citing works

mRNA-based cancer therapeutics

Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500 · see citing works

Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

Xie, H., Ma, K., Zhang, K., Zhou, J., Li, L., Yang, W., Gong, Y., Cai, L., & Gong, K. (2021) · Cell Death & Disease · doi:10.1038/s41419-020-03229-8 · Cited by 155 · see citing works

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139 · see citing works

Nanoplatforms for mRNA Therapeutics

Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · see citing works

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States

Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80 · see citing works

Small-molecule correctors and stabilizers to target p53

Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44 · see citing works

ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ

БАЗАРБАЕВА, Ә. А., Майгельдиева, Ш. М., & ЖҮНДІБАЕВА, Т. Н. (2023) · Pedagogy and Psychology · doi:10.51889/2077-6861.2023.1.30.016

Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)

Кaмирдиновa, Н., & Кaлиевa, Ш. С. (2018) · DOAJ (DOAJ: Directory of Open Access Journals)

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

A GEOMETRIC MEAN IN THE FURUTA INEQUALITY

Fujii, M., & Nakamoto, R. (2002) · Scientiae mathematicae Japonicae · Cited by 15 · see citing works